Can Covid-19 Affect Your Mitochondria?

Mitochondria

Mitochondria

Beth talks with Steven Engle, Chief Executive Officer and Director of CohBar, Inc, a biotechnology company developing mitochondria-based therapeutics to treat chronic diseases and extend healthy lifespan. The company’s lead compound, CB4211, is in early stage clinical trial for fatty liver disease and obesity. The company also has four preclinical programs, two in cancer, one in fibrotic diseases, one in type 2 diabetes, and one, which we discuss here, in COVID-19 associated acute respiratory syndrome. You can find more at the company website. The interview starts at about 6 minutes.
Host:Beth Bennett
Executive Producer: Beth Bennett
Show Producer: Beth Bennett
Listen to the show:

Play
Share
Beth Bennett tagged this post with: , , , , Read 72 articles by

Leave a Reply

Your email address will not be published. Required fields are marked *

Support KGNU


How On Earth is produced by a small group of volunteers at the studios of KGNU, an independent community radio station in the Boulder-Denver metro area. KGNU is supported by the generosity and efforts of community members like you. Visit kgnu.org to learn more.

Podcast

Subscribe via iTunes
 
How On Earth episodes can be downloaded as podcasts via iTunes, or streamed to a mobile device via Stitcher or Science360 Radio.
 
Listen on Stitcher
 
Listen on Science360 Radio
 
For more info about podcasting, and more subscription options, visit our Podcast page.